1Jemal A, Siegel R, Xu J, et al. (2010) Cancer statistics. CA Cancer J Clin 60, 277–300.
2Escobar EL, Gomes-Marcondes MC & Carvalho HF (2009) Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth. Prostate 69, 548–558.
3Brown MD, Hart C, Gazi E, et al. (2010) Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer. Br J Cancer 102, 403–413.
4Berquin IM, Min Y, Wu R, et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117, 1866–1875.
5Reese AC, Fradet V & Witte JS (2009) Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics 2, 149–158.
6Kristal AR, Arnold KB, Neuhouser ML, et al. (2010) Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 172, 566–577.
7Vissapragada S, Ghosh A, Ringer L, et al. (2010) Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2x Pten(+/ − ) preclinical mouse model. Cell Cycle 9, 1824–1829.
8Szymanski KM, Wheeler DC & Mucci LA (2010) Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92, 1223–1233.
9Hori S, Butler E & McLoughlin J (2011) Prostate cancer and diet: food for thought? BJU Int 107, 1348–1359.
10Spaccarotella KJ, Kris-Etherton PM, Stone WL, et al. (2008) The effect of walnut intake on factors related to prostate and vascular health in older men. Nutr J 7, 13.
11Freedland SJ & Aronson WJ (2009) Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol 19, 263–267.
12Lloyd JC, Antonelli JA, Phillips TE, et al. (2010) Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. J Urol 183, 1619–1624.
13Hardman WE & Ion G (2008) Suppression of implanted MDA-MB 231 human breast cancer growth in nude mice by dietary walnut. Nutr Cancer 60, 666–674.
14Hardman WE, Ion G, Akinsete JA, et al. (2011) Dietary walnut suppressed mammary gland tumorigenesis in the C(3)1 TAg mouse. Nutr Cancer 63, 960–970.
15Nguewa PA & Calvo A (2010) Use of transgenic mice as models for prostate cancer chemoprevention. Curr Mol Med 10, 705–718.
16Petrik MB, McEntee MF, Johnson BT, et al. (2000) Highly unsaturated (n-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc(Min/+) mice. J Nutr 130, 2434–2443.
17Ju YH, Clausen LM, Allred KF, et al. (2004) β-Sitosterol, β-sitosterol glucoside, and a mixture of β-sitosterol and β-sitosterol glucoside modulate the growth of estrogen-responsive breast cancer cells in vitro and in ovariectomized athymic mice. J Nutr 134, 1145–1151.
18Maguire LS, O'Sullivan SM, Galvin K, et al. (2004) Fatty acid profile, tocopherol, squalene and phytosterol content of walnuts, almonds, peanuts, hazelnuts and the macadamia nut. Int J Food Sci Nutr 55, 171–178.
19Han DH, Lee MJ & Kim JH (2006) Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res 26, 3601–3606.
20Berquin IM, Edwards IJ & Chen YQ (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269, 363–377.
21Hsu A, Bray TM, Helferich WG, et al. (2010) Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med (Maywood) 235, 90–97.
22Jacobs DR Jr, Gross MD & Tapsell LC (2009) Food synergy: an operational concept for understanding nutrition. Am J Clin Nutr 89, 1543S–1548S.
23Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123, 1939–1951.
24Gupta S, Adhami VM, Subbarayan M, et al. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64, 3334–3343.
25Qi J, Nakayama K, Cardiff RD, et al. (2010) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18, 23–38.
26Xu R, Yokoyama WH, Irving D, et al. (1998) Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 137, 29–36.
27Brown MB & Forsythe AB (1974) Robust tests for equality of variances. J Amer Statist Assoc 69, 364–367.
28Laird NM & Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38, 963–974.
29Kris-Etherton PM, Hu FB, Ros E, et al. (2008) The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr 138, 1746S–1751S.
30Adhami VM, Siddiqui IA, Ahmad N, et al. (2004) Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64, 8715–8722.
31Wang L, Bonorden MJ, Li GX, et al. (2009) Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila Pa) 2, 484–495.
32Wang L, Zhang J, Zhang Y, et al. (2011) Lobe-specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate and their responses to chemopreventive selenium. Prostate 71, 1429–1440.
33Freedland SJ, Mavropoulos J, Wang A, et al. (2008) Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68, 11–19.
34Cheon EC, Strouch MJ, Barron MR, et al. (2011) Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice. Int J Cancer 128, 2783–2792.
35Quiner TE, Nakken HL, Mason BA, et al. (2011) Soy content of basal diets determines the effects of supplemental selenium in male mice. J Nutr 141, 2159–2165.
36Zhang J, Wang L, Li G, et al. (2011) Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer 63, 778–789.
37Key TJ (2011) Diet, insulin-like growth factor-1 and cancer risk. Proc Nutr Soc .
38Prasad AS, Mukhtar H, Beck FW, et al. (2010) Dietary zinc and prostate cancer in the TRAMP mouse model. J Med Food 13, 70–76.
39Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8, 915–928.
40Bonorden MJ, Rogozina OP, Kluczny CM, et al. (2009) Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice. Nutr Cancer 61, 265–275.
41Thomas JA 2nd, Antonelli JA, Lloyd JC, et al. (2010) Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 13, 350–355.
42Chen LH, Fang J, Sun Z, et al. (2009) Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr 139, 653–659.
43Gualberto A & Pollak M (2009) Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10, 923–936.
44Majeed N, Blouin MJ, Kaplan-Lefko PJ, et al. (2005) A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24, 4736–4740.
45Anzo M, Cobb LJ, Hwang DL, et al. (2008) Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 68, 3342–3349.
46Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, et al. (2008) Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68, 3495–3504.
47Raina K, Blouin MJ, Singh RP, et al. (2007) Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67, 11083–11091.
48Housa D, Vernerova Z, Heracek J, et al. (2008) Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression. Neoplasma 55, 442–446.
49Chung WH, Kim TH, Chang IH, et al. (2009) Relation of resistin to prostate cancer differentiation and aggressiveness. Korean J Urol 50, 540–546.
50Kim HJ, Lee YS, Won EH, et al. (2010) Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int 108, E77–E83.
51Housa D, Vernerova Z, Heracek J, et al. (2008) Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 57, 451–458.
52Grosman H, Fabre B, Mesch V, et al. (2010) Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male 13, 87–92.
53Aronis KN, Vamvini MT, Chamberland JP, et al. (2011) Short-term walnut consumption increases circulating total adiponectin and apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study. Metabolism .
54Solomon KR, Pelton K, Boucher K, et al. (2009) Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 174, 1017–1026.
55Llaverias G, Danilo C, Wang Y, et al. (2010) A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol 177, 3180–3191.
56Krycer JR, Kristiana I & Brown AJ (2009) Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3. PLoS ONE 4, e8496.
57Krauss RM (2010) Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 21, 305–311.
58Kok DE, van Roermund JG, Aben KK, et al. (2011) Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis 14, 340–345.
59Ohlsson C, Mohan S, Sjogren K, et al. (2009) The role of liver-derived insulin-like growth factor-I. Endocr Rev 30, 494–535.
60Brasky TM, Till C, White E, et al. (2011) Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 173, 1429–1439.
61Risbridger GP, Davis ID, Birrell SN, et al. (2010) Breast and prostate cancer: more similar than different. Nat Rev Cancer 10, 205–212.
62Hoffmann I (2003) Transcending reductionism in nutrition research. Am J Clin Nutr 78, 514S–516S.